Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

Company Overview

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.81 million shs
• Average Volume: N/A
• Market Capitalization: A$196.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PAR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Computer Hardware
• Current Symbol: ASX:PAR
• CIK: N/A
• Web: www.paradigmbiopharma.com
• Phone: 61 3 9629 5566
• Fax: N/A
• Employees: 1,480
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$58.65 million
• Net Margins: -89,138.58%
• Pretax Margin: N/A
• Return on Equity: -203.64%
• Return on Assets: -86.16%

Debt

• Debt-to-Equity Ratio: 1.01
• Current Ratio: 7.22
• Quick Ratio: 5.93

Sales & Book Value

• Annual Sales: A$79.22 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 6.44
• Book Value: A$0.08 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 350,360,000
• Free Float: N/A
• Market Cap: A$196.66 million
• Optionable: Not Optionable
• Beta: 0.94